<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567853</url>
  </required_header>
  <id_info>
    <org_study_id>MEMO3D.Reg</org_study_id>
    <nct_id>NCT00567853</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair</brief_title>
  <acronym>MEMO3D</acronym>
  <official_title>Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorin Group USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorin Group USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data on the effectiveness and clinical outcomes of
      the MEMO 3D Annuloplasty ring as used for mitral valve repair.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with successful repair at 6 months.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from re-operation at 12 months. Preoperative and postoperative mitral valve regurgitation and LV dimensions and mass assessed by echocardiography. Actuarial survival and freedom from clinical events at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>MEMO 3D ring</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients in the study will be implanted with the MEMO 3D ring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of the MEMO 3D Annuloplasty Ring</intervention_name>
    <description>Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.</description>
    <arm_group_label>MEMO 3D ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is 18 years old or older

          -  An annuloplasty ring is indicated for reinforcement of a dysfunctional or diseased
             native mitral valve according to the current medical practice for valvular repair at
             each site.

          -  The subject is able to return for all follow-up evaluations of the study.

        Exclusion Criteria:

          -  The subject or subject's legal representative is unwilling to sign the informed
             consent.

          -  The subject is or will be participating in another medical device or drug clinical
             trial.

          -  The subject is a minor, prisoner, institutionalized, or is unable to give informed
             consent.

          -  The subject has a life expectance of less than 1 year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clark Hargrove, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Presbyterian Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Presbyterian Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral valve regurgitation</keyword>
  <keyword>mitral valve disease</keyword>
  <keyword>mitral valve repair</keyword>
  <keyword>mitral valve dysfunction</keyword>
  <keyword>heart valve</keyword>
  <keyword>valve disease</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

